BeiGene Change in Assets/Liabilities 2014-2024 | ONC
BeiGene annual/quarterly change in assets/liabilities history and growth rate from 2014 to 2024. Change in assets/liabilities can be defined as represents any other changes in assets/liabilities
- BeiGene change in assets/liabilities for the quarter ending September 30, 2024 was $0.009B, a 103.43% decline year-over-year.
- BeiGene change in assets/liabilities for the twelve months ending September 30, 2024 was $-0.271B, a 55.93% decline year-over-year.
- BeiGene annual change in assets/liabilities for 2023 was $-0.243B, a 55.39% increase from 2022.
- BeiGene annual change in assets/liabilities for 2022 was $-0.156B, a 152.46% decline from 2021.
- BeiGene annual change in assets/liabilities for 2021 was $0.298B, a 464.6% decline from 2020.
BeiGene Annual Change in Assets/Liabilities
(Millions of US $) |
| 2023 |
$-243 |
| 2022 |
$-156 |
| 2021 |
$298 |
| 2020 |
$-82 |
| 2019 |
$-43 |
| 2018 |
$-71 |
| 2017 |
$10 |
| 2016 |
$-3 |
| 2015 |
$-11 |
| 2014 |
$-2 |
| 2013 |
$8 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
|
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|
